Cargando…

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

Detalles Bibliográficos
Autores principales:	Aylwin, Simon J. B., Bodi, Istvan, Beaney, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996872/ https://www.ncbi.nlm.nih.gov/pubmed/26115708 http://dx.doi.org/10.1007/s11102-015-0663-4

Ejemplares similares

Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
por: Chik, Constance L, et al.
Publicado: (2021)

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
por: Brastianos, Priscilla K., et al.
Publicado: (2014)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
por: Di Stefano, Anna Luisa, et al.
Publicado: (2020)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
por: Żołek, Teresa, et al.
Publicado: (2023)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma
por: Larkin, Sarah Jane, et al.
Publicado: (2014)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
por: Sondermann, Wiebke, et al.
Publicado: (2015)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
por: Chan, Sze Wai, et al.
Publicado: (2015)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
por: Rao, Mayank, et al.
Publicado: (2019)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
por: Guzzetti, Carlotta, et al.
Publicado: (2023)

A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
por: Clark, Mary, et al.
Publicado: (2022)

Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
por: Rao, Mayank, et al.
Publicado: (2023)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
por: Gavric, Ana Ursula, et al.
Publicado: (2018)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
por: Maleka, A., et al.
Publicado: (2016)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo, Mª del Carmen, et al.
Publicado: (2021)

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
por: Broudic-Guibert, Morgane, et al.
Publicado: (2019)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

Spontaneous rupture of malignant papillary craniopharyngioma with CSF seeding and metastatic deposits: A case report and literature review
por: Baig Mirza, Asfand, et al.
Publicado: (2022)

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2018)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
por: Vidarsdottir, Linda, et al.
Publicado: (2020)

Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2022)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
por: Fasano, Morena, et al.
Publicado: (2022)

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model
por: Danysh, Brian P., et al.
Publicado: (2016)

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
por: Joshi, Monika, et al.
Publicado: (2015)

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer
por: Chen, Shitu, et al.
Publicado: (2020)

First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report
por: Dao, Bao D., et al.
Publicado: (2015)

Value of magnetic resonance imaging in predicting BRAF mutation in craniopharyngiomas
por: Giordano, Mario, et al.
Publicado: (2019)

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas
por: Gouravan, Sarina, et al.
Publicado: (2018)

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
por: Kopetz, Scott, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7jnm8sousu0sq6srn0ghd028mb